^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Vulvar Cancer

    20h
    TG4001.12: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers (clinicaltrials.gov)
    P1/2, N=143, Active, not recruiting, Transgene | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Bavencio (avelumab) • tipapkinogene sovacivec (TG4001)
    2d
    Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, City of Hope Medical Center | N=126 --> 0 | Initiation date: Dec 2025 --> Jul 2026 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal
    3d
    Unexpected Discovery of Myoepithelioma-Like Tumor of the Vulvar Region After Trauma: A Rare Case Report and Systematic Review of the Literature. (PubMed, J Cutan Pathol)
    These findings confirm the diagnosis of MELTVR. Although the biological behaviors of MELTVR remain incompletely understood, recognition of its characteristic morphologic and immunophenotypic profiles will aid in distinguishing it from potential histological mimics better.
    Journal
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • EWSR1 (EWS RNA Binding Protein 1) • CD34 (CD34 molecule) • VIM (Vimentin) • FUS (FUS RNA Binding Protein) • GFAP (Glial Fibrillary Acidic Protein)
    3d
    STRIVE: STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision (clinicaltrials.gov)
    P=N/A, N=249, Recruiting, British Columbia Cancer Agency | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Nov 2031 | Trial primary completion date: Dec 2025 --> Nov 2031
    Enrollment open • Trial completion date • Trial primary completion date
    4d
    DOSTCONICG: The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Cukurova University
    New trial
    6d
    [177Lu]Lu-AKIR001 First-in-human Study (clinicaltrials.gov)
    P1, N=15, Recruiting, Karolinska University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF wild-type
    7d
    A Prospective Single-Arm Exploratory Study on CT-Based Radiomics Combined with Clinical Parameters for Predicting Lymph Node Metastasis in Gynecological Malignancies (Cervical, Ovarian, Endometrial and Vulval Cancers) (ChiCTR2500113585)
    P=N/A, N=350, Not yet recruiting, The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University
    New trial
    7d
    A cohort study on the impact of modified open three-incision surgical approach on survival prognosis of vulvar cancer (ChiCTR2500113300)
    P=N/A, N=502, Completed, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New trial
    9d
    Malignant vascular neoplasms of the distal female genital tract: a series of 19 cases emphasizing unusual features and diagnostic challenges. (PubMed, Histopathology)
    While many morphologic features of vascular lesions at this site are shared with those of extra-genital soft tissues, pathologists must be aware that these tumours may occur in the vulvovaginal area and display unconventional clinical profiles. As such, a broad differential for epithelioid and spindle cell neoplasms at this site is prudent.
    Journal
    |
    CAMTA1 (Calmodulin Binding Transcription Activator 1)
    9d
    e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study (clinicaltrials.gov)
    P=N/A, N=23, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    14d
    Diagnostic Performance of the ASCL1/ZNF582 Methylation Test for Detection of High-Grade Vulvar Intraepithelial Neoplasia and Vulvar Cancer. (PubMed, Mol Diagn Ther)
    In conclusion, the ASCL1/ZNF582 methylation assay accurately detects high-grade VIN and vulvar cancer, while minimizing the detection of benign and low-grade lesions, indicating its clinical value.
    Journal
    |
    MIR24-2 (MicroRNA 24-2) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • MIR124-2 (MicroRNA 124-2)
    |
    PreCursor-M AnoGYN Methylation Assay
    16d
    Vulvar dermatofibrosarcoma protuberans in a 55-year-old female: A case report, surgical reconstruction approach and literature review. (PubMed, Gynecol Oncol Rep)
    Single-stage radical excision with immediate reconstruction can achieve favorable oncologic and functional outcomes in vulvar DFSP. Long-term surveillance remains essential due to the potential for late local recurrence.
    Journal
    |
    CD34 (CD34 molecule)